Life Science Sweden recognizes Ilya Pharma
In press
Ilya Pharma selected for Springboard’s Health Innovation Hub
Ilya Pharma joins the ranks of globally recognized brands including Rebiotix, later acquired by Ferring, the first company in microbiome to recruit to a phase III trial. About Springboard Enterprises: Springboard Enterprises' mission is to accelerate the growth of entrepreneurial companies led by women through access to essential resources and a global community of experts. Since 2000, over 800 Springboard portfolio companies seeking investment of financial and human capital for product development and expansion have created $20 Billion in value via equity investments, 20 IPOs and 200 acquisitions by strategic partners. Springboard entrepreneurs are transforming industries.
Ilya Pharmas technology explained in a nice conversation in - Discovery Matters
Pod cast Discovery matters, episode 13. Scratched knees, smelly yogurt, and speedy wound healing
Four young Nordic life science entrepreneurs wins prestigious award
Evelina Vågesjö, CEO and cofounder Ilya Pharma, Hans Genee, Lauri Sippola and Erik Gatenholm have all been recognized by MIT Technology Review European Innovators under 35
Ilya Pharma interviewed by the real estate company Vasakronan, facilitating growth of companies in Uppsala Science Park
We advocate more pharmaceutical products to be tested in clinical trials to meet relevant efficacy endpoints and deliver clinical value in different wound segments.
Ilya Pharma interviewed in seminar of climate for growth companies in Uppsala County i
Mia Phillipson, Professor and co-founder of Ilya Pharma is sharing our growth story and future strategy at Uppsalaväxer in Almedalen-a political festival in Visby, Gotland.
Professor Mia Phillipson in prestigious scientific podcast describing the immune system and recent advances.
Professor Mia Phillipson, co-founder of Ilya Pharma is giving the view of our immune system, the scientific advances as well as opening up for using and targeting the immune system in development of next-generation biologics to treat current unmet medical needs. In Swedish. https://play.acast.com/s/alltduvelatveta/198omimmunforsvaretmedmiaphillipson